O'Brien Patrick

COO Patrick O'Brien sold 49,493 shares for $3,123,349.43 across 12 transactions on 2026-01-05

Patrick O'Brien, Chief Operating Officer of Arrowhead Pharmaceuticals, executed 12 separate sales totaling 49,493 shares for $3,123,349.43 on 2026-01-05, reducing his holdings from 524,401 to 474,908 shares (a 9.4% reduction). This is significant given his prior 5 trades at ARWR, all of which were sells that proved well-timed at the 90-day mark, with 4 of 5 showing negative 90-day returns ranging from -23.2% to -47.9%; his cross-ticker track record also shows a 100.00% well-timed rate across 11 prior sales with an average 90-day return of -28.5%. The stock is trading near its 52-week high at $63.88 (just 9.8% below the $70.82 peak) and has gained 4.0% over 30 days and 74.8% over 90 days, creating a backdrop where a large insider sale from an operator with a demonstrated pattern of favorable exit timing may signal caution, though the company remains unprofitable with net income of $-175,241,000.00 over its most recent full fiscal year. Investors should note the magnitude of this multi-tranche sale and compare it against O'Brien's historical execution at this specific ticker before drawing conclusions about forward outlook.

COO Patrick O'Brien sells 37,184 shares (37.2K shares) for $736,058.62 ($736.1K) across 3 transactions on ARWR amid -50.2% drawdown from 52-week high

Patrick O'Brien, the company's Chief Operating Officer and General Counsel, executed 3 separate sales totaling 37,184 shares (37.2K shares) for $736,058.62 ($736.1K) on January 6–7, 2025, at a blended average price of $19.80. This represents a 6.6% reduction in his holdings to 527,201 shares (527.2K shares). The timing is notable: Arrowhead trades at $19.67, down -50.2% from its 52-week high of $39.48 and down -16.7% over the past 30 days. His prior trades at this ticker show a consistent pattern—all 5 of his previous sales at ARWR were followed by further declines over the subsequent 90 days (90-day returns ranged from -2.0% to -26.8%), and across his cross-ticker open-market history, his 90-day well-timed rate stands at 100.00%, indicating a strong historical record of selling into strength. Underlying fundamentals remain challenged: the company reported zero quarterly revenue and a -$170.8M net loss in its most recent period, with annual revenue declining -98.5% year-over-year. The combination of a senior executive's continued selective selling, deteriorating financial performance, and the stock's sharp descent from highs warrants investor attention to near-term operational developments.